A pooled analysis of 4 randomized controlled trials published in the Patient journal aimed at assessing the impact of treatment with canagliflozin in comparison with placebo or sitagliptin on health-related quality-of-life outcomes in individuals with type 2 diabetes mellitus. It was found that candidates who were treated with canagliflozin were more likely to express interest in continuing study medication than those who were administered placebo or sitagliptin [odds ratio (95% confidence interval) of 1.54 (1.19-1.99); p = 0.001]. In addition, individuals treated with canagliflozin were more likely to be satisfied with their weight and reported favorable outcomes in terms of physical and emotional health (either score improvement or maintenance of good scores). The investigators thus suggested that individuals with type 2 diabetes mellitus treated with canagliflozin generally had positive experiences with treatment and improvements in health-related quality of life.